Advertisement

Analysis of mitochondrial DNA allelic changes in Parkinson’s disease: a preliminary study

  • Tiziana CasoliEmail author
  • Rosamaria Lisa
  • Paolo Fabbietti
  • Fiorenzo Conti
Short Communication

Abstract

Background

Mitochondrial DNA (mtDNA) mutations are considered as a possible primary cause of age-associated neurodegenerative disorders like Parkinson’s disease (PD).

Aims

To analyze, along the whole mtDNA sequence of PD patients, the presence of non-reference alleles compared to reference alleles, as defined in the revised Cambridge Reference Sequence (rCRS).

Methods

mtDNA was extracted from whole blood of PD and control groups, and was sequenced using a chip-based resequencing system.

Results

58 nucleotide positions (np) exhibited a different allelic distribution in the two groups; in 81% of them the non-reference alleles were over-represented in PD patients, similar to findings reported in patients with Alzheimer’s disease, albeit in reduced proportion. Closer analysis of the 58 np in PD group showed that they were characterized by low-level heteroplasmy, and that the nucleotide substitutions determined an amino acid change in 84% of cases.

Conclusions

These results suggest that mtDNA allelic changes are increased in PD and that age-related neurodegenerative diseases could share a common mechanism involving mtDNA.

Keywords

Parkinson’s disease mtDNA MitoChip Resequencing Neurodegeneration 

Notes

Acknowledgments

We would like to thank all people who contributed to Report-AGE database management. In addition we wish to acknowledge the help of Belinda Giorgetti and Moreno Solazzi in laboratory procedures. This work was supported by the “Current Research” fund of the Italian Ministry of Health to IRCCS INRCA.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the IRCCS INRCA Ethical Committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Supplementary material

40520_2019_1197_MOESM1_ESM.pdf (186 kb)
Supplementary file1 (PDF 185 kb)
40520_2019_1197_MOESM2_ESM.pdf (193 kb)
Supplementary file2 (PDF 193 kb)

References

  1. 1.
    Schapira AH, Cooper JM, Dexter D et al (1990) Mitochondrial complex I deficiency in Parkinson's disease. J Neurochem 54:823–827CrossRefGoogle Scholar
  2. 2.
    Devi L, Raghavendran V, Prabhu BM et al (2008) Mitochondrial import and accumulation of alpha-synuclein impair complex I in human dopaminergic neuronal cultures and Parkinson disease brain. J Biol Chem 283:9089–9100CrossRefGoogle Scholar
  3. 3.
    Guardia-Laguarta C, Area-Gomez E, Rüb C et al (2014) α-Synuclein is localized to mitochondria-associated ER membranes. J Neurosci 34:249–259CrossRefGoogle Scholar
  4. 4.
    Hsieh CH, Shaltouki A, Gonzalez AE et al (2016) Functional impairment in miro degradation and mitophagy is a shared feature in familial and sporadic Parkinson's disease. Cell Stem Cell 19:709–724CrossRefGoogle Scholar
  5. 5.
    Esteves AR, Domingues AF, Ferreira IL et al (2008) Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background. Mitochondrion 8:219–228CrossRefGoogle Scholar
  6. 6.
    Hua F, Zhang X, Hou B et al (2017) Relationship between mitochondrial DNA A10398G polymorphism and Parkinson's disease: a meta-analysis. Oncotarget 8:78023–78030Google Scholar
  7. 7.
    Coxhead J, Kurzawa-Akanbi M, Hussain R et al (2016) Somatic mtDNA variation is an important component of Parkinson's disease. Neurobiol Aging 38:217.e1–217.e6CrossRefGoogle Scholar
  8. 8.
    Smigrodzki R, Parks J, Parker WD (2004) High frequency of mitochondrial complex I mutations in Parkinson's disease and aging. Neurobiol Aging 25:1273–1281CrossRefGoogle Scholar
  9. 9.
    Khusnutdinova E, Gilyazova I, Ruiz-Pesini E et al (2008) A mitochondrial etiology of neurodegenerative diseases: evidence from Parkinson's disease. Ann N Y Acad Sci 1147:1–20CrossRefGoogle Scholar
  10. 10.
    Lin MT, Cantuti-Castelvetri I, Zheng K et al (2012) Somatic mitochondrial DNA mutations in early Parkinson and incidental Lewy body disease. Ann Neurol 71:850–854CrossRefGoogle Scholar
  11. 11.
    Hoekstra JG, Hipp MJ, Montine TJ et al (2016) Mitochondrial DNA mutations increase in early stage Alzheimer disease and are inconsistent with oxidative damage. Ann Neurol 80:301–306CrossRefGoogle Scholar
  12. 12.
    Casoli T, Spazzafumo L, Di Stefano G et al (2015) Role of diffuse low-level heteroplasmy of mitochondrial DNA in Alzheimer's disease neurodegeneration. Front Aging Neurosci 7:142CrossRefGoogle Scholar
  13. 13.
    Bustacchini S, Abbatecola AM, Bonfigli AR et al (2015) Report-Age study group. The Report-AGE project: a permanent epidemiological observatory to identify clinical and biological markers of health outcomes in elderly hospitalized patients in Italy. Aging Clin Exp Res 27:893–901CrossRefGoogle Scholar
  14. 14.
    Postuma RB, Berg D, Stern M et al (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 30:1591–1601CrossRefGoogle Scholar
  15. 15.
    Hu J, Zou F, Wright FA (2005) Practical FDR-based sample size calculations in microarray experiments. Bioinformatics 21:3264–3272CrossRefGoogle Scholar
  16. 16.
    Carpenter GI, Hastie CL, Morris JN et al (2006) Measuring change in activities of daily living in nursing home residents with moderate to severe cognitive impairment. BMC Geriatr 3:7CrossRefGoogle Scholar
  17. 17.
    Coon KD, Valla J, Szelinger S et al (2006) Quantitation of heteroplasmy of mtDNA sequence variants identified in a population of AD patients and controls by array-based resequencing. Mitochondrion 6:194–210CrossRefGoogle Scholar
  18. 18.
    Hochberg Y, Benjamini Y (1990) More powerful procedures for multiple significance testing. Stat Med 9:811–818CrossRefGoogle Scholar
  19. 19.
    Edgar R, Domrachev M, Lash AE (2002) Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30:207–210CrossRefGoogle Scholar
  20. 20.
    Pyle A, Anugrha H, Kurzawa-Akanbi M et al (2016) Reduced mitochondrial DNA copy number is a biomarker of Parkinson's disease. Neurobiol Aging 38:216.e7–216.e10CrossRefGoogle Scholar
  21. 21.
    Shoffner JM, Brown MD, Torroni A et al (1993) Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17:171–184CrossRefGoogle Scholar
  22. 22.
    Coskun P, Wyrembak J, Schriner SE et al (2012) A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 1820:553–564CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Center for Neurobiology of AgingIRCCS INRCAAnconaItaly
  2. 2.Scientific DirectionIRCCS INRCAAnconaItaly
  3. 3.Diagnostic Unit of Geriatric PharmacoepidemiologyIRCCS INRCACosenzaItaly
  4. 4.Section of Neuroscience and Cell Biology, Department of Experimental and Clinical MedicineUniversità Politecnica Delle MarcheAnconaItaly

Personalised recommendations